Clorox – The consumer goods giant’s earnings surged. It’s also rebounding from last year’s cyberattacks. “Everything is back to normal and there’s huge demand for their products,” Jim quickly said at Friday’s morning meeting. Tesla, the leader in electric vehicles, is recalling 2.2 million vehicles due to warning light issues. Remember, our Super Six means getting rid of Tesla; no more Super Seven. Jim says maybe don’t buy the slide. “I urge people to rethink that maybe (Elon Musk) is no longer as interested as CEO.” Bristol-Myers Squibb – After earnings beat forecasts and 2024 outlook topped estimates The drugmaker’s shares rose. “Bristol-Myers Squibb’s five-year plan,” Jim said, is that unless the company can develop more drugs. Members of the CNBC Investing Club know that Eli Lilly and Company is our favorite drug stock . Abbvie — The drugmaker reported mixed quarterly results for some but raised its forecasts. Abbvie loses exclusivity on blockbuster Humira Jim said the firm stock price shows “they’re going to be able to handle the lows.” Exxon Mobil and Chevron — Both oil giants saw profits rise. Chevron shares rose 3% after it raised its dividend following rumors it would be unable to pay the dividend. Jim said, “If you have to own oil, we like Kotla” and own it for the club. He prefers Chevron to ExxonMobil.
